Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro.

Expert opinion on drug metabolism & toxicology - 1 Jan 2000

Gao Yuan, Ma Jingjing

Abstract excerpt

BACKGROUND: Tacrolimus is a immunosuppressant drug in transplantation with a narrow therapeutic range and high pharmacokinetic variability. Clinical studies have revealed that POR*28 contributes enhanced tacrolimus clearance in CYP3A5 expressers. However, it remains unknown that how exactly the POR polymorphism could influence the metabolism of tacrolimus via CYP3A5 in vitro. RESEARCH DESIGN & METHODS: A503V is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype
Share to Hep G2 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to NADPH-Ferrihemoprotein Reductase

Share to Polymorphism, Single Nucleotide

Share to Tacrolimus

Source

Identifiers

PMID: 35946839
DOI: 10.1080/17425255.2022.2112174

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro.PMID 35946839Read ↗

Impact of POR*28 Variant on Tacrolimus Pharmacokinetics in Kidney Transplant Patients with Different CYP3A5 Genotypes.Semantic proximity Read ↗

CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.Semantic proximity Read ↗

The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.Semantic proximity Read ↗

The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.Semantic proximity Read ↗

CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study.Semantic proximity Read ↗

Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.Semantic proximity Read ↗

CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort studySemantic proximity Read ↗

Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.Semantic proximity Read ↗

Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation.Semantic proximity Read ↗

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.Semantic proximity Read ↗

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.Semantic proximity Read ↗

Pharmacogenomic Determinants of Post-Liver Transplant Diabetes Mellitus: A Systematic Review and In Silico Pharmacogenomic AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.